These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29073495)

  • 41. STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.
    Nabhani S; Schipp C; Miskin H; Levin C; Postovsky S; Dujovny T; Koren A; Harlev D; Bis AM; Auer F; Keller B; Warnatz K; Gombert M; Ginzel S; Borkhardt A; Stepensky P; Fischer U
    Clin Immunol; 2017 Aug; 181():32-42. PubMed ID: 28579554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autoimmune lymphoproliferative immunodeficiencies (ALPIDs): A proposed approach to redefining ALPS and other lymphoproliferative immune disorders.
    Magerus A; Rensing-Ehl A; Rao VK; Teachey DT; Rieux-Laucat F; Ehl S
    J Allergy Clin Immunol; 2024 Jan; 153(1):67-76. PubMed ID: 37977527
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic Testing in Patients with Autoimmune Lymphoproliferative Syndrome: Experience of 802 Patients at Cincinnati Children's Hospital Medical Center.
    Xu X; Denton J; Wu Y; Liu J; Guan Q; Dawson DB; Bleesing J; Zhang W
    J Clin Immunol; 2024 Jul; 44(7):166. PubMed ID: 39060684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Somatic loss of heterozygosity, but not haploinsufficiency alone, leads to full-blown autoimmune lymphoproliferative syndrome in 1 of 12 family members with FAS start codon mutation.
    Hauck F; Magerus-Chatinet A; Vicca S; Rensing-Ehl A; Roesen-Wolff A; Roesler J; Rieux-Laucat F
    Clin Immunol; 2013 Apr; 147(1):61-68. PubMed ID: 23524443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).
    Teachey DT; Seif AE; Grupp SA
    Br J Haematol; 2010 Jan; 148(2):205-16. PubMed ID: 19930184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
    Hsu AP; Dowdell KC; Davis J; Niemela JE; Anderson SM; Shaw PA; Rao VK; Puck JM
    Genet Med; 2012 Jan; 14(1):81-9. PubMed ID: 22237435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.
    Price S; Shaw PA; Seitz A; Joshi G; Davis J; Niemela JE; Perkins K; Hornung RL; Folio L; Rosenberg PS; Puck JM; Hsu AP; Lo B; Pittaluga S; Jaffe ES; Fleisher TA; Rao VK; Lenardo MJ
    Blood; 2014 Mar; 123(13):1989-99. PubMed ID: 24398331
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synergistic defects of novo FAS and homozygous UNC13D leading to autoimmune lymphoproliferative syndrome-like disease: A 10-year-old Chinese boy case report.
    Gu H; Ma J; Chen Z; Wang J; Zhang R; Wu R
    Gene; 2018 Sep; 672():45-49. PubMed ID: 29864493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular genetic studies in lymphocyte apoptosis and human autoimmunity.
    Martin DA; Combadiere B; Hornung F; Jiang D; McFarland H; Siegel R; Trageser C; Wang J; Zheng L; Lenardo MJ
    Novartis Found Symp; 1998; 215():73-82; discussion 82-91. PubMed ID: 9760572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatic mosaicism for a NRAS mutation associates with disparate clinical features in RAS-associated leukoproliferative disease: a report of two cases.
    Shiota M; Yang X; Kubokawa M; Morishima T; Tanaka K; Mikami M; Yoshida K; Kikuchi M; Izawa K; Nishikomori R; Okuno Y; Wang X; Sakaguchi H; Muramatsu H; Kojima S; Miyano S; Ogawa S; Takagi M; Hata D; Kanegane H
    J Clin Immunol; 2015 Jul; 35(5):454-8. PubMed ID: 25896945
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
    Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
    Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.
    López-Nevado M; González-Granado LI; Ruiz-García R; Pleguezuelo D; Cabrera-Marante O; Salmón N; Blanco-Lobo P; Domínguez-Pinilla N; Rodríguez-Pena R; Sebastián E; Cruz-Rojo J; Olbrich P; Ruiz-Contreras J; Paz-Artal E; Neth O; Allende LM
    Front Immunol; 2021; 12():671755. PubMed ID: 34447369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of inherited defects decreasing Fas function in autoimmunity.
    Dianzani U; Chiocchetti A; Ramenghi U
    Life Sci; 2003 May; 72(25):2803-24. PubMed ID: 12697265
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How I treat autoimmune lymphoproliferative syndrome.
    Rao VK; Oliveira JB
    Blood; 2011 Nov; 118(22):5741-51. PubMed ID: 21885601
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnosis of autoimmune lymphoproliferative syndrome caused by FAS deficiency in adults.
    Lambotte O; Neven B; Galicier L; Magerus-Chatinet A; Schleinitz N; Hermine O; Meyts I; Picard C; Godeau B; Fischer A; Rieux-Laucat F
    Haematologica; 2013 Mar; 98(3):389-92. PubMed ID: 22983577
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polymorphisms in FAS and CASP8 genes may contribute to the development of ALPS phenotype: a study in 25 patients with probable ALPS.
    Tan Ç; Özgül RK; Çağdaş Ayvaz D; Tezcan İ; Sanal Ö
    Turk J Pediatr; 2015; 57(2):141-5. PubMed ID: 26690594
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complete CD95/FAS deficiency due to complex homozygous germline TNFRSF6 mutations in an adult patient with mild autoimmune lymphoproliferative syndrome (ALPS).
    Tessarin G; Mazza C; Baronio M; Gazzurelli L; Rossi S; Moratto D; Badolato R; Rensing-Ehl A; Ehl S; Warnatz K; Rosanelli C; Morello E; Plebani A; Lougaris V
    Clin Immunol; 2021 Jul; 228():108757. PubMed ID: 33992756
    [No Abstract]   [Full Text] [Related]  

  • 58. Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations.
    Poppema S; Maggio E; van den Berg A
    Leuk Lymphoma; 2004 Mar; 45(3):423-31. PubMed ID: 15160902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).
    Marega LF; Teocchi MA; Dos Santos Vilela MM
    Clin Exp Immunol; 2016 Aug; 185(2):148-53. PubMed ID: 27060458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome.
    Carrasquillo JA; Chen CC; Price S; Whatley M; Avila NA; Pittaluga S; Jaffe ES; Rao VK
    Clin Nucl Med; 2019 Dec; 44(12):949-955. PubMed ID: 31689275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.